Friday, December 14, 2018

Althea

Expanding upon our existing capabilities in biologics manufacturing, Althea is establishing itself as a premier, US-based provider for high-containment ADC bioconjugate manufacturing as well as fill and finish services for both HPAPIs and ADCs. Our state-of-the-art 57,000 sq ft facility is located a few miles from our Roselle Street campus in San Diego, CA. The facility and our service offerings...

celares GmbH

celares GmbH, established 2003, is a Contract Development and Manufacturing Organization (CDMO) providing customized services as well as innovative solutions for antibody-drug conjugates or ADCs. The company uniquely combines expertise in both synthetic and protein chemistry and has experiences in handling toxins, synthesis of activated linkers, toxin-linker-precursors, and ADCs.  celares also offers its proprietary PaSmax® linker technology for next generation...

MabPlex

MabPlex, founded in 2013, is a specialized, global CRO/CMO service provider, offering one-stop biologics development and manufacturing solutions to customers with a services from cell line development and process development to GMP manufacturing. The company's technical expertise allows them to provide effective and high-quality solutions for monoclonal antibody therapeutics and antibody-drug conjugate (ADC) to the biopharmaceutical industry. MabPlex USA, Inc. 2978 Scott...

AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative...

MedImmune

MedImmune, the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology, respiratory disease, inflammation, autoimmunity, cardiovascular disease, metabolic disease, neuroscience, and infection and vaccines. Since its founding of the company in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond...

Quanta BioDesign, Ltd

Quanta BioDesign, Ltd.  in was founded 1997 for the purpose of developing and commercializing an extensive line of products for companies involved in drug discovery and diagnostic development programs.  The company's products are based on  proprietary discrete polyethylene glycol (dPEG®) chemistries, including a the processes for making these compounds.  The single molecular weight ethylene glycol conjugation technology, dPEG eliminates common...

QPS Holdings

Founded in 1995, QPS is a contract research organization (CRO) that tests drug candidates for major pharmaceutical companies.  The company is GLP/GCP-compliant, supporting discovery, preclinical and clinical drug development.  As part of the services, the company provides quality services to pharmaceutical and biotechnology clients worldwide. Their linearly integrated core competencies include Neuropharmacology, DMPK, Toxicology, Bioanalysis. Translational medicine, Early Stage Clinical...

Redwood Bioscience Inc

Redwood Bioscience Inc., a biopharmaceutical company, engages in developing precision protein-chemical engineering technology designed for developing and optimizing the next-generation antibody-drug conjugates and other semi-synthetic biotherapeutics. The company's site specific protein modification platform provides control over cargo placement on a protein, cargo orientation, and stoichiometry, enabling the creation of conjugate libraries from which homogenous compounds can be selected. 5703 Hollis...

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi.  Phase III studies are in progress with EYLEA in two additional indications...

SAFC Global / SAFC Biosciences

Antibody-drug conjugation (ADC) technology uses monoclonal antibodies or other biologics to deliver conjugated highly-potent APIs (HPAPIs) to targeted cells. In conjugated form, the HPAPI exhibits more selective cytotoxicity, thereby, sparing non-target cells from many of the toxic effects. For antibody drug conjugates (ADCs), SAFC®, a member of Sigma-Aldrich, can conjugate biological molecules with high-potent APIs (HPAPIs) to meet pharmaceutical industry...

Related articles